India

Cadila gets nod for Phase III trials of vaccine

Our Correspondent

The Subject Expert Committee of Central Drugs Standard Control Organisation (CDSCO) that met on January 1 and 2, 2021 has granted the permission to Cadila Healthcare Ltd for conduct of the Phase III clinical trial of the Novel Corona Virus-2019-nCov-Vaccine it has developed.

The firm initiated Phase-I/II clinical trial in India in more than 1,000 participants which is ongoing. The interim data suggests that the vaccine is safe and immunogenic with three doses when administered intradermally. Accordingly, firm has sought permission to conduct Phase-III clinical trial in 26,000 Indian participants, which has been recommended by the Subject Expert Committee.

The approval for the third phase of trials for Cadila Healthcare Ltd came even as the CDSCO approved vaccines of M/s Serum and M/s Bharat Biotech for restricted use in emergency situation.

The Gulf Indians

Recent Posts

Systamatic Persecution of Christians in India

Joseph Maliakan  Seven months  of January to July 2025 , witnessed an unprecedented 334 incidents…

1 month ago

Muscat to Host 2025 Youth Ambassadors Programme, Expanding Regional Participation and Global Engagement

Muscat : Set to take place in Muscat this October, the 2025 edition of the…

2 months ago

ADNOC Gas Signs 10-Year LNG Supply Deal with Hindustan Petroleum

Dubai: ADNOC Gas has entered into a 10-year agreement to supply liquefied natural gas (LNG)…

2 months ago

Supreme Court rules against Criminalising Protest

Joseph Maliakan In a great relief to political, social and human rights activists in the…

2 months ago

ED CANNOT BE A SUPER COP : Supreme Court and High Court

By Joseph MaiakanThe Enforcement Directorate ( ED ) the long arm of the Modi government…

2 months ago

Indian School Al Seeb Mourns the Loss of Beloved Educator Ms. Lekha Jackson

Muscat: The Indian School Al Seeb (ISAS) community is deeply saddened by the passing of…

2 months ago

This website uses cookies.